Market revenue in 2023 | USD 30.0 million |
Market revenue in 2030 | USD 94.3 million |
Growth rate | 17.8% (CAGR from 2023 to 2030) |
Largest segment | Pneumococcal conjugate vaccine |
Fastest growing segment | Pneumococcal Conjugate Vaccine |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 93% in 2023. Horizon Databook has segmented the South Africa pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In May 2023, South Africa's decision to procure pneumococcal vaccines from an Indian company, Cipla, instead of local manufacturer Biovac raised questions about the country's vaccine procurement policy. This decision came at a time when South Africa was hosting an international meeting on mRNA vaccine production, highlighting the tension between local production and price pressures.
The procurement decision coincided with a meeting in Cape Town, where international delegates gathered to discuss mRNA vaccine technology transfer. South Africa's mRNA hub, based at Afrigen Biologics, aims to share vaccine production knowledge with 15 other Low- and Middle-Income Countries (LMICs).
South Africa's Health Minister emphasized the government's commitment to local vaccine development but noted that procurement decisions were governed by legislation. The government is reviewing its procurement policy to better support local production in the future.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa pneumococcal vaccine market, including forecasts for subscribers. This country databook contains high-level insights into South Africa pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account